Abstract
No public abstract is available from the verified source records.
Panagiota Anyfanti, Christina Antza, Eleni Korki, Eleni Aintinidou, Kyriakos Papadopoulos, Elena Angeloudi, Vasilios Kotsis
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1016/s0140-6736(19)32008-2
10.1016/s0140-6736(19)32008-2
Unresolved referenced work
Kept as external metadata until matched
10.1016/s0140-6736(21)01330-1
10.1016/s0140-6736(21)01330-1
10.1038/ki.2015.142
10.1038/ki.2015.142
10.1093/ajh/hpad121
10.1093/ajh/hpad121
Overview of monogenic or Mendelian forms of hypertension
10.3389/fped.2019.00263 · 2019
10.1161/hypertensionaha.121.16498
10.1161/hypertensionaha.121.16498
10.1080/10641963.2022.2132012
10.1080/10641963.2022.2132012
Genetics of Essential Hypertension: From Families to Genes
10.1097/01.asn.0000032524.13069.88 · 2002
10.1093/eurheartj/ehx134
10.1093/eurheartj/ehx134
Heritability and Stability of Resting Blood Pressure in Australian Twins
10.1375/twin.9.2.205 · 2006
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Hypertension: genes versus environment
10.1016/s0140-6736(94)92762-6 · 1994
10.1371/journal.pcbi.1002822
10.1371/journal.pcbi.1002822
10.1038/nrg2344
10.1038/nrg2344
10.1038/nature10405
10.1038/nature10405
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals
10.1038/s41588-018-0303-9 · 2019
10.1038/s41588-018-0205-x
10.1038/s41588-018-0205-x
An Academic Clinician’s Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX
10.1161/hypertensionaha.120.14535 · 2021
Improving performance of polygenic risk scores for hypertension across two ancestry groups
10.1371/journal.pone.0353311 · 2026
Precision Hypertension
10.1161/hypertensionaha.123.21710 · 2024
10.1016/j.phrs.2017.04.031
10.1016/j.phrs.2017.04.031
10.1038/s41576-018-0018-x
10.1038/s41576-018-0018-x
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
10.1038/s41588-018-0183-z · 2018
Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk
10.1161/hypertensionaha.120.16471 · 2021
A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood
10.1038/s41467-022-31080-2 · 2022
Human essential hypertension: no significant association of polygenic risk scores with antihypertensive drug responses
10.1038/s41598-020-68878-3 · 2020
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
10.1161/atvbaha.123.319220 · 2024
Blood Pressure Polygenic Score Predicts Long-Term Blood Pressure Control and Treatment-Resistant Hypertension
2026
Unresolved referenced work
Kept as external metadata until matched
10.1016/j.jacbts.2021.04.004
10.1016/j.jacbts.2021.04.004
Abstract 4362610: Safety, Pharmacokinetics, and Pharmacodynamics of SGB-3908, A siRNA Targeting AGT in Healthy and Mildly Hypertensive Subjects
2025
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis
10.1097/crd.0000000000000645 · 2025
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
10.1056/nejmoa2208391 · 2023
RNA Interference With Zilebesiran for Mild to Moderate Hypertension The KARDIA-1 Randomized Clinical Trial
10.1001/jama.2024.0728 · 2024
Add-On Treatment with Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
10.1001/jama.2025.6681 · 2025
Unresolved referenced work
2025
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
10.1056/nejmoa1704154
10.1056/nejmoa1704154 · doi-reference
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
10.1016/j.jacc.2026.02.5092 · doi-reference
Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease
10.1161/hypertensionaha.122.18731 · doi-reference
CRISPR/Cas9 Mediated Deletion of the Angiotensinogen Gene Reduces Hypertension: A Potential for Cure?
10.1161/hypertensionaha.120.16870 · doi-reference
Human Germline Genome Editing
10.1016/j.ajhg.2017.06.012 · doi-reference
10.1016/s0092-8674(01)00241-0
10.1016/s0092-8674(01)00241-0 · doi-reference
Search-and-replace genome editing without double-strand breaks or donor DNA
10.1038/s41586-019-1711-4 · doi-reference
10.1038/nature17946
10.1038/nature17946 · doi-reference
10.1126/science.1258096
10.1126/science.1258096 · doi-reference
10.1038/s41586-021-03534-y
10.1038/s41586-021-03534-y · doi-reference
Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials
10.1007/s00228-026-04179-4 · doi-reference